Ixekizumab May Improve Renal Function in Psoriasis

Ixekizumab May Improve Renal Function in Psoriasis

Background: Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis. Case report: In this paper, we report a patient...

Full description

Bibliographic Details
Main Authors:	Giuseppe Fabrizio Amoruso, Steven Paul Nisticò, Luigi Iannone, Emilio Russo, Giuseppe Rago, Cataldo Patruno, Luigi Bennardo
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Healthcare
Subjects:	ixekizumab psoriasis chronic renal failure
Online Access:	https://www.mdpi.com/2227-9032/9/5/543

Similar Items

No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis
by: Therezia Bokor-Billmann, et al.
Published: (2019-04-01)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018-01-01)

Long-term management of pediatric psoriasis with ixekizumab: a case report
by: Diego Orsini, et al.
Published: (2023-12-01)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020-03-01)

Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis
by: Mwangi J. Murage, et al.
Published: (2021-01-01)

Ixekizumab
by: İlgen Ertam Sağduyu
Published: (2022-04-01)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
by: Martina Burlando, et al.
Published: (2022-11-01)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
by: Bruce W. Kirkham, et al.
Published: (2023-07-01)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
by: Luís Puig, et al.
Published: (2019-08-01)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017-06-01)

Disease response and patient-reported outcomes among initiators of ixekizumab
by: Mona Shahriari, et al.
Published: (2022-04-01)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017-11-01)

Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
by: Lajos Kemény, et al.
Published: (2019-01-01)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
by: Blauvelt A, et al.
Published: (2020-03-01)

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
by: Alexander Egeberg, et al.
Published: (2022-10-01)

Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice
by: Craig Leonardi, et al.
Published: (2022-05-01)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017-04-01)

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab
by: Andrew Blauvelt, et al.
Published: (2018-04-01)

Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature
by: Pablo Santa María, et al.
Published: (2017-10-01)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
by: Alexander Egeberg, et al.
Published: (2023-01-01)

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
by: Adam Reich, et al.
Published: (2023-12-01)

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
by: Alexander Egeberg, et al.
Published: (2023-03-01)

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
by: Shany Sherman, et al.
Published: (2020-12-01)

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
by: Alice B. Gottlieb, et al.
Published: (2023-07-01)

Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12
by: Alice B. Gottlieb, et al.
Published: (2022-01-01)

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
by: Masaru Honma, et al.
Published: (2020-09-01)

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial
by: Kristian Reich, et al.
Published: (2022-05-01)

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
by: Lynda Spelman, et al.
Published: (2022-01-01)

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension
by: Alexandra B. Kimball, et al.
Published: (2017-10-01)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
by: Saxon D. Smith, et al.
Published: (2023-06-01)

Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis
by: Xin Mu, et al.
Published: (2021-10-01)

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)
by: Jennifer Soung, et al.
Published: (2023-06-01)

Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials
by: Yonghong Zhang, et al.
Published: (2024-03-01)

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center
by: I-Heng Chiu, et al.
Published: (2023-06-01)

Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
by: Luis E. Sánchez-Dueñas, MD, et al.
Published: (2020-07-01)

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
by: Andrea Chiricozzi, et al.
Published: (2023-12-01)

Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
by: Kristian Reich, et al.
Published: (2017-05-01)